HUDSON, N.Y., May 03, 2017 -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it will expand the offering of a key Alzheimer’s Disease (AD) mouse model, APPSWE - Model 1349, to include aged animals.
Taconic will now offer off-the-shelf Model 1349 animals aged up to 42 weeks, saving months off the typical timeline to access Alzheimer’s models. This program addresses customers’ need to have critical disease models immediately available, as opposed to placing an order and waiting for the animals to age and express the desired phenotype.
Dr. Michael Seiler, Taconic Biosciences’ portfolio director for genetically engineered models, commented, “The addition of aged APPSWE animals demonstrates Taconic’s commitment to help researchers reduce discovery timelines. These reductions save both time and money, ultimately making it easier to progress towards life-changing therapeutics.”
APPSWE mice express a mutated form of the human gene for amyloid precursor protein (APP) known as the Swedish mutation (APPSWE). The mutated gene encodes a double amino acid substitution and is associated with an inheritable increased susceptibility to Alzheimer’s Disease. Resulting phenotypic manifestations in APPSWE mice include a progressive accumulation of beta amyloid (Aβ) in the brain, analogous to classic “senile plaques” of human AD, and correlated cognitive deficits. Mice that overexpress an Alzheimer’s-associated isoform of the human amyloid precursor protein provide a model for human Alzheimer’s Disease and an experimental tool for a diversity of cellular mechanisms.
Alzheimer’s Disease and other dementias is expected to cost the United States $259 billion dollars in 2017 (www.alz.org), representing a major market and focus for pharmaceutical research.
Taconic also offers unaged Model 1349 animals, as well as a comprehensive neuroscience rodent model portfolio. To learn more about Taconic’s neuroscience portfolio, please contact Taconic Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe or at [email protected]
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact: Kelly Owen Grover Director of Marketing Communications (518) 697-3824 [email protected]


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



